Synonym
Omilancor, BT-11; BT11; BT 11;
IUPAC/Chemical Name
piperazine-1,4-diylbis((6-(1H-benzo[d]imidazol-2-yl)pyridin-2-yl)methanone)
InChi Key
MVHWZNBAQIGPOQ-UHFFFAOYSA-N
InChi Code
InChI=1S/C30H24N8O2/c39-29(25-13-5-11-23(31-25)27-33-19-7-1-2-8-20(19)34-27)37-15-17-38(18-16-37)30(40)26-14-6-12-24(32-26)28-35-21-9-3-4-10-22(21)36-28/h1-14H,15-18H2,(H,33,34)(H,35,36)
SMILES Code
O=C(N1CCN(C(C2=NC(C3=NC4=CC=CC=C4N3)=CC=C2)=O)CC1)C5=NC(C6=NC7=CC=CC=C7N6)=CC=C5
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
528.58
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Yafeng F, Xinpeng S, Rong W, Guofeng C. Omilancor mitigates the senescence of
nucleus pulposus cells induced by DDP through targeting MAP2K6. Aging (Albany
NY). 2024 Mar 20;16(6):5050-5064. doi: 10.18632/aging.205588. Epub 2024 Mar 20.
PMID: 38517363; PMCID: PMC11006466.
2: Tubau-Juni N, Bassaganya-Riera J, Leber AJ, Alva SS, Hontecillas R. Oral
Omilancor Treatment Ameliorates Clostridioides difficile Infection During IBD
Through Novel Immunoregulatory Mechanisms Mediated by LANCL2 Activation. Inflamm
Bowel Dis. 2024 Jan 5;30(1):103-113. doi: 10.1093/ibd/izad124. PMID: 37436905.
3: Tubau-Juni N, Hontecillas R, Leber A, Maturavongsadit P, Chauhan J,
Bassaganya-Riera J. First-in-class topical therapeutic omilancor ameliorates
disease severity and inflammation through activation of LANCL2 pathway in
psoriasis. Sci Rep. 2021 Oct 6;11(1):19827. doi: 10.1038/s41598-021-99349-y.
PMID: 34615968; PMCID: PMC8494925.
4: Leber A, Hontecillas R, Tubau-Juni N, Lichtiger S, Bassaganya-Riera J.
WITHDRAWN: EFFICACY, SAFETY, AND TOLERABILITY OF OMILANCOR IN A PHASE 2
RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF PATIENTS WITH ULCERATIVE
COLITIS. Inflamm Bowel Dis. 2022 Jan 22;28(Suppl 1):S112. doi:
10.1093/ibd/izac015.180. Retraction in: Inflamm Bowel Dis. 2022 Dec
1;28(12):1938. doi: 10.1093/ibd/izac055. PMID: 35104848.
5: Leber A, Hontecillas R, Tubau-Juni N, Lichtiger S, Bassaganya-Riera J.
Correction to: Efficacy, Safety, and Tolerability of
Omilancor in a Phase 2
Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Ulcerative
Colitis. Inflamm Bowel Dis. 2022 Dec 1;28(12):1938. doi: 10.1093/ibd/izac055.
PMID: 35489068.
6: Tubau-Juni N, Hontecillas R, Leber AJ, Alva SS, Bassaganya-Riera J. Treating
Autoimmune Diseases With LANCL2 Therapeutics: A Novel Immunoregulatory Mechanism
for Patients With Ulcerative Colitis and Crohn's Disease. Inflamm Bowel Dis.
2024 Apr 3;30(4):671-680. doi: 10.1093/ibd/izad258. PMID: 37934790.
